A few people with type 1 diabetes undergo multiple hospital admissions for acute glycaemic events. We report on a series of five such 'frequent flyers' who were provided with continuous subcutaneous insulin infusion (CSII) therapy. Mean HbA1c decreased from 9.7 +/- 2.5% (83 +/- 27 mmol/mol) to 7.9 +/- 0.4% (63 +/- 4.7 mmol/mol) after 2-4 months. Frequency of admissions for acute glycaemic events reduced in three but increased in two patients within 6 months. Total insulin dose and body mass index decreased in some patients and satisfaction was anecdotally higher. Some, but not all, 'frequent flyers' benefited from a trial of CSII
We compared the effects of continuous subcutaneous insulin infusion (CSII) and multi-daily insulin i...
We compared the effects of continuous subcutaneous insulin infusion (CSII) and multi-daily insulin i...
Aims: To assess HbA1c values and hospitalization rates before, during and after continuous subcutane...
Optimal blood glucose control and the restoration of physiological insulin secretion is an ongoing m...
Background: Continuous subcutaneous insulin infusion (CSII) and intensive multiple daily insulin inj...
INTRODUCTION: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a tre...
AbstractIntroductionThe continuous subcutaneous insulin infusion (CSII) is an alternative to multipl...
Introduction: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a tre...
Background: Evaluations of continuous subcutaneous insulin infusion (CSII) usually focus on one pre...
Aims: Patients with Type 1 diabetes and poor glycaemic control frequently display unfavourable lipid...
Use of continuous subcutaneous insulin infusion (CSII) in adults with type 1 diabetes has become inc...
To assess in a randomized crossover trial the efficacy of continuous subcutaneous insulin infusion i...
Aims. To determine whether multiple daily injections (MDIs) or continuous subcutaneous insulin infus...
AIM: To study the effect of continuous subcutaneous insulin infusion (CSII) on metabolic control and...
Both Continuous Subcutaneous Insulin Infusion (CSI) and Multiple Daily Injections (MDI) are effectiv...
We compared the effects of continuous subcutaneous insulin infusion (CSII) and multi-daily insulin i...
We compared the effects of continuous subcutaneous insulin infusion (CSII) and multi-daily insulin i...
Aims: To assess HbA1c values and hospitalization rates before, during and after continuous subcutane...
Optimal blood glucose control and the restoration of physiological insulin secretion is an ongoing m...
Background: Continuous subcutaneous insulin infusion (CSII) and intensive multiple daily insulin inj...
INTRODUCTION: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a tre...
AbstractIntroductionThe continuous subcutaneous insulin infusion (CSII) is an alternative to multipl...
Introduction: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a tre...
Background: Evaluations of continuous subcutaneous insulin infusion (CSII) usually focus on one pre...
Aims: Patients with Type 1 diabetes and poor glycaemic control frequently display unfavourable lipid...
Use of continuous subcutaneous insulin infusion (CSII) in adults with type 1 diabetes has become inc...
To assess in a randomized crossover trial the efficacy of continuous subcutaneous insulin infusion i...
Aims. To determine whether multiple daily injections (MDIs) or continuous subcutaneous insulin infus...
AIM: To study the effect of continuous subcutaneous insulin infusion (CSII) on metabolic control and...
Both Continuous Subcutaneous Insulin Infusion (CSI) and Multiple Daily Injections (MDI) are effectiv...
We compared the effects of continuous subcutaneous insulin infusion (CSII) and multi-daily insulin i...
We compared the effects of continuous subcutaneous insulin infusion (CSII) and multi-daily insulin i...
Aims: To assess HbA1c values and hospitalization rates before, during and after continuous subcutane...